TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,094,256 | +180.5% | 122,400 | +381.9% | 0.51% | +184.3% |
| Q2 2023 | $390,098 | -85.8% | 25,397 | -79.2% | 0.18% | -92.0% |
| Q1 2023 | $2,740,047 | +6.9% | 121,834 | 0.0% | 2.23% | +46.7% |
| Q4 2022 | $2,562,169 | -6.1% | 121,834 | +10.1% | 1.52% | -2.4% |
| Q3 2022 | $2,728,000 | +8.1% | 110,698 | +6.3% | 1.56% | +2.2% |
| Q2 2022 | $2,524,000 | +201.2% | 104,150 | +220.5% | 1.52% | +185.9% |
| Q1 2022 | $838,000 | -50.1% | 32,501 | -39.9% | 0.53% | -60.1% |
| Q4 2021 | $1,679,000 | +22.1% | 54,103 | -4.6% | 1.34% | +46.9% |
| Q3 2021 | $1,375,000 | +76.1% | 56,694 | +6.0% | 0.91% | +64.3% |
| Q2 2021 | $781,000 | +27.0% | 53,498 | +117.3% | 0.55% | +21.2% |
| Q1 2021 | $615,000 | – | 24,622 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |